



For Immediate Release

Aciont® CEO to Present at IN3 West Medical Device Conference

John Higuchi will present on behalf of Aciont Inc at the IN3 West Medical Device Conference in Las Vegas, NV on February 22, 2011.

Salt Lake City, UT – February 8, 2011 - Aciont Inc. announces that John Higuchi, the company's chief executive officer, will present at the upcoming Investment in Innovation (IN3) West medical device conference at the Venetian Resort-Hotel-Casino in Las Vegas, NV on Tuesday, February 22, 2011, 10:30AM PST. The meeting is hosted by Elsevier Business Intelligence.

The presentation will provide updates on the company's ophthalmic, non-invasive, controlled and sustained release technologies and relevant products in development addressing sight threatening diseases such as severe uveitis, diabetic macular edema, diabetic retinopathy and age-related macular degeneration.

The IN3 West conference features numerous emerging medical technology companies and will be attended by investment bankers, venture capitalists, analysts and executives from biotechnology and pharmaceutical companies. Information about the conference can be found at: www.in3west.com.

Aciont Inc. is a specialty biopharmaceutical company endeavoring to become the world leader in commercializing localized, non-invasive (topical passive diffusion-based and iontophoretic), controlled and sustained release back of the eye therapeutics for sight threatening diseases such as severe uveitis, diabetic macular edema and age-related macular degeneration. Aciont's goal is to provide ophthalmologists substantially greater freedom in treating and/or preventing chronic eye diseases through optimal drug dosing and improved patient/physician compliance. Aciont is located in Salt Lake City, Utah. For more information, visit the company's website at www.aciont.com.

Source: Aciont Inc.

Contact

John Higuchi, CEO
Aciont, Inc.
(801) 359-3461
admin@aciont.com